Laatste proeven

EudraCT Number: 2020-001211-24 Sponsor Protocol Number: DRM06-AD07/J2T-DM-KGAA Start Date:
Sponsor Name: Dermira, Inc., a wholly-owned subsidiary of Eli Lilly and Company
Full Title: A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
Medical condition: Atopic dermatitis
Disease: Version SOC Term Classification Code Term Level
21.1 100000004858 10003639 Atopic dermatitis LLT
Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
Trial protocol: PL (Ongoing) DE (Completed) LV (Ongoing) LT (Ongoing) EE (Ongoing) FR (Completed) BG (Ongoing) ES (Ongoing)
Trial results: (No results available)
EudraCT Number: 2016-003643-10 Sponsor Protocol Number: NAM Start Date:
Sponsor Name: UMC Utrecht
Full Title: Modulating regulatory T cell function in JIA with Vitamin B3 (nicotinamide) treatment
Medical condition: Juvenile idiopathic arthritis (JIA)
Disease: Version SOC Term Classification Code Term Level
Population Age: Children, Adolescents, Under 18 Gender: Male, Female
Trial protocol: NL (Ongoing)
Trial results: (No results available)
EudraCT Number: 2008-008254-23 Sponsor Protocol Number: SIG112851 Start Date:
Sponsor Name: GlaxoSmithKline Research & Development Limited
Full Title: A randomised, double-blind, placebo-controlled, 2-way crossover study to determine the efficacy of repeat inhaled doses of GW870086X on FEV1 in mild to moderate asthmatics
Medical condition: Asthma
Disease: Version SOC Term Classification Code Term Level
9.1 10003555 Asthma bronchial LLT
Population Age: Adults Gender: Male, Female
Trial protocol: DE (Completed)
Trial results: View results
EudraCT Number: 2006-001589-17 Sponsor Protocol Number: KN 38-7271-001 Start Date:
Sponsor Name: KeyNeurotek Pharmaceuticals AG
Full Title: A doubel-blind, parallel-group, Phase IIa study to investigate the efficacy, safety and pharmacokinetics of two dose levels of KN 38-7271 versus placebo in comatose patients with severe traumatic b...
Medical condition: Comatose patients with traumatic brain injury (TBI).
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults Gender: Male, Female
Trial protocol: DE (Completed) BE (Completed) CZ (Completed)
Trial results: (No results available)
EudraCT Number: 2009-011152-22 Sponsor Protocol Number: GTG003.08 Start Date:
Sponsor Name: GENETHON
Full Title: Phase 1/2 clinical trial of haematopoietic stem cell gene therapy for the Wiskott-Aldrich Syndrome
Medical condition: Phase 1/2 clinical trial of haematopoietic stem cell gene therapy for the Wiskott-Aldrich Syndrome. An open labelled, non-randomised, phase I/II, cohort study involving a single infusion of autolo...
Disease: Version SOC Term Classification Code Term Level
Population Age: Children, Adolescents, Under 18 Gender: Male
Trial protocol: FR (Completed)
Trial results: View results
EudraCT Number: 2016-003673-18 Sponsor Protocol Number: 1062016 Start Date:
Sponsor Name: UZ Brussel
Full Title: Can we with vitamin D3, improve the innate immune system?
Medical condition: Immunological problems such as hypogammaglobulinemia with clinical recurrent infections such as sinusitis , pneumonia , otitis , skin infections and gastrointestinal infections.
Disease: Version SOC Term Classification Code Term Level
Population Age: Children, Adolescents, Under 18 Gender: Male, Female
Trial protocol: BE (Ongoing)
Trial results: (No results available)
EudraCT Number: 2010-022844-19 Sponsor Protocol Number: Start Date:
Sponsor Name: CHU de Dijon
Full Title: Randomized phase III study of a treatment driven by early PET response compared to a treatment not monitored by early PET in patients with Ann Arbor Stage III-IV or high risk IIB Hodgkin lymphoma
Medical condition: Hodgkin Lymphoma not previously treated
Disease: Version SOC Term Classification Code Term Level
12.1 10020328 Hodgkin's lymphoma LLT
Population Age: Adolescents, Under 18, Adults Gender: Male, Female
Trial protocol: FR (Completed) BE (Completed)
Trial results: (No results available)
EudraCT Number: 2018-004154-25 Sponsor Protocol Number: CLCZ696B2319E1 Start Date:
Sponsor Name: Novartis Pharma AG
Full Title: A multicenter study to evaluate long-term safety and tolerability of open label sacubitril/valsartan in pediatric patients with heart failure due to systemic left ventricle systolic dysfunction wh...
Medical condition: Pediatric heart failure : Patients (≥ 13 months) with HF due to systemic left ventricular systolic dysfunction. [Note: All patients per protocol for the core study CLCZ696B2319 (PANORAMA-HF) ...
Disease: Version SOC Term Classification Code Term Level
20.0 100000004849 10019279 Heart failure LLT
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
Trial protocol: PL (Ongoing) FR (Ongoing) BG (Ongoing) PT (Ongoing) CZ (Completed) ES (Ongoing) HU (Ongoing) HR (Ongoing) DE (Completed) AT (Completed) IT (Ongoing) FI (Completed)
Trial results: (No results available)
EudraCT Number: 2021-000497-28 Sponsor Protocol Number: PTC923-MD-004-PKU Start Date:
Sponsor Name: PTC Therapeutics, Inc.
Full Title: Phase 3 Open-Label Study of PTC923 (Sepiapterin) in Phenylketonuria
Medical condition: Metabolic Disorders - Phenylketonuria
Disease: Version SOC Term Classification Code Term Level
20.0 100000004850 10034873 Phenylketonuria (PKU) LLT
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing) ES (Ongoing) PT (Ongoing) DK (Ongoing) NL (Ongoing) IT (Ongoing)
Trial results: (No results available)
EudraCT Number: 2007-003913-15 Sponsor Protocol Number: ANTRAG01 Start Date:
Sponsor Name: Medical University Innsbruck
Full Title: Wirkung von Oxcarbazepin (Trileptal) auf den Kortikosteroid-Metabolismus - Pilotstudie
Medical condition: Oxcarbazepin, a widely-used antiepileptic treatment is evaluated with respect to Cortisol-degradation. Young adults and adults with oxcarbazepine monotherapy since at least 6 months and temporal lo...
Disease: Version SOC Term Classification Code Term Level
Population Age: Adolescents, Under 18, Adults Gender: Male
Trial protocol: AT (Ongoing)
Trial results: (No results available)

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren